Effect of TXA on Reducing Bruising After Filler Injection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-05

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to look at the effect tranexamic acid (TXA) may have on reducing bruising, swelling, and pain after facial filler injection. The main question it aims to answer is:

* Does the addition of TXA to hyaluronic acid (HA) reduce bruising, swelling, and tenderness after HA injection?

Participants will receive the study medication along with the standard facial filler injection and complete surveys.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of Tranexamic Acid in Facial Fillers

NCT04373603

Injection Site Bruising

WITHDRAWN PHASE4

Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study

NCT06345833

Hemophilia Hemorrhage Facelift Surgery

RECRUITING EARLY_PHASE1

Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis

NCT05774717

Surgery Postoperative Blood Loss

RECRUITING PHASE1

EFFECTS OF TRANEXAMIC ACID IN TUMESCENT SOLUTION FOR LIPOSUCTION PROCEDURES

NCT06648265

Liposuction Bruising Inflammation +4 more

COMPLETED PHASE4

The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery

NCT04951128

Edema Ecchymosis; Eyelid

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The overall purpose of this study is to evaluate the safety and efficacy of co-administration of TXA with HA in reducing swelling, bruising and pain after facial injection. Researchers will do this by comparing HA to HA+TXA in participants undergoing facial filler injections. Participants undergoing facial filler injections almost always have the same type of injection performed bilaterally in order to maintain symmetry. This provides a unique opportunity where participants can serve as their own controls. Therefore, researchers have designed this as a half face study. Participants will be injected with HA on half of their face and the other half of the face will be injected with HA+TXA. Researchers will then assess swelling, bruising, pain, and overall satisfaction using participant self-reported surveys, physician surveys, and review of medical records.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Facial Filler Injections Hyaluronic Acid Tranexamic Acid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Facial Filler Injection

TXA plus HA injection in half of face, saline plus HA injection on other half of face

Group Type EXPERIMENTAL

Hyaluronic Acid (HA)

Intervention Type PROCEDURE

Injectable gel

Tranexamic Acid (TXA)

Intervention Type DRUG

Injection of TXA

Saline (placebo)

Intervention Type DRUG

Injection of saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyaluronic Acid (HA)

Injectable gel

Intervention Type PROCEDURE

Tranexamic Acid (TXA)

Injection of TXA

Intervention Type DRUG

Saline (placebo)

Injection of saline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age equal to or greater than 18 but less than or equal to 89 years.
* Participants interested in facial filler (HA) injection.
* English speaking.

Exclusion Criteria

* Minors or under the age of 18
* Participant over the age of 89
* Pregnant or breast-feeding women
* Individuals unable to give consent due to another condition such as impaired decision-making capacity.
* Individuals with a history of a thrombotic event (DVT, PE, stroke, MI) or genetic disorder that increases risk of thrombosis
* Concurrent use of estrogen
* Participants undergoing unilateral facial filler (HA) injection
* Participants with history of hypersensitivity to TXA or any of the other ingredients
* Participants that are on current therapeutic anticoagulation therapy and aspirin use
* Participants with stage 2 or greater renal failure
* Participants on hemodialysis or peritoneal dialysis
* History of diabetes or seizures
* Current tobacco smokers
* Acquired defective color vision

Minimum Eligible Age

18 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes